Propranolol ( DrugBank: Propranolol )

6 diseases

6. パーキンソン病

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-004629-18-NL (EUCTR)	13/04/2017	17/01/2017	The influence of stress on Parkinson's tremor	The noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach - Noradrenergic basis of Parkinson tremor	Tremor in Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Propranolol Product Name: Propranolol HCl CF 40 mg tablet Product Code: RVG 55618	Radboud University Nijmegen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Netherlands

臨床試験数 : 108 / 薬物数 : 67 - (DrugBank : 17) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02104011 (ClinicalTrials.gov)	May 22, 2015	1/4/2014	Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers	Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers: Pilot Trial	Renal Angiomyolipomas;Tuberous Sclerosis	Drug: Propranolol	University Hospital, Bordeaux	NULL	Completed	18 Years	N/A	All	2	Phase 2	France

臨床試験数 : 20 / 薬物数 : 39 - (DrugBank : 10) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00651235 (ClinicalTrials.gov)	February 2007	3/3/2008	A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome	A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome	Marfan Syndrome	Drug: Losartan and Atenolol or Propranolol;Drug: Atenolol or Propranolol	National Taiwan University Hospital	NULL	Recruiting	1 Year	N/A	Both	44	Phase 2	Taiwan

臨床試験数 : 22 / 薬物数 : 48 - (DrugBank : 19) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 49

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04713657 (ClinicalTrials.gov)	March 30, 2022	13/1/2021	Beta-blocker Administration for Cardiomyocyte Division	Mechanistic Clinical Trial of Beta-Blocker Administration For Reactivating Cardiomyocyte Division In Tetrology of Fallot	Tetralogy of Fallot	Other: N-thymidine;Other: Urine Collection;Procedure: Echocardiogram;Procedure: Cardiac MRI;Drug: Propranolol Hydrochloride;Drug: Placebo;Procedure: Physical Exam;Other: Specimen Collection	Bernhard Kuhn	University of Pittsburgh	Not yet recruiting	N/A	2 Months	All	40	Phase 1	United States

臨床試験数 : 54 / 薬物数 : 73 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04113187 (ClinicalTrials.gov)	June 23, 2020	27/9/2019	Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients	Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients	Hereditary Hemorrhagic Telangiectasia;Osler Weber Rendu Disease	Drug: Propranolol treatment;Drug: Placebo	University Hospital, Bordeaux	AMRO-HHT-France - Association Maladie de Rendu-Osler	Active, not recruiting	18 Years	N/A	All	15	Phase 3	France

臨床試験数 : 22 / 薬物数 : 27 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000008498	2012/07/25	24/07/2012	Propranolol for a treatment of lymphatic malformation		lymphatic malformation	propranolol therapy	University of Tokyo	NULL	Complete: follow-up complete	Not applicable	65years-old	Male and Female	20	Phase 2	Japan